Clopidogrel indications
Pro Research Analysisby 
Searched over 200M research papers for "clopidogrel indications"
Clopidogrel Indications in Cardiovascular Disease
Clopidogrel is widely used as an antiplatelet medication for the treatment and secondary prevention of several cardiovascular conditions. Its main indications include acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD) . In these settings, clopidogrel is often combined with aspirin as part of dual antiplatelet therapy (DAPT), especially after events like ACS or percutaneous coronary intervention (PCI) Patti2020Johnson2012.
Acute Coronary Syndrome and Percutaneous Coronary Intervention
Clopidogrel is a key component of DAPT for patients with ACS, both in the acute phase and for secondary prevention. It is also indicated for patients undergoing PCI, particularly when newer P2Y12 inhibitors (such as prasugrel or ticagrelor) are contraindicated or not tolerated due to increased bleeding risk Patti2020Johnson2012Wójcik2021. In some cases, patients may be switched from newer agents to clopidogrel to reduce bleeding risk .
Stroke and Transient Ischemic Attack (TIA)
For patients with very high-risk TIA or minor stroke, short-term DAPT with clopidogrel plus aspirin for 21–28 days, followed by clopidogrel monotherapy for up to 90 days, is recommended to reduce the risk of recurrent events . Clopidogrel is also used as monotherapy for secondary prevention in patients who cannot tolerate aspirin .
Peripheral Artery Disease (PAD)
Clopidogrel monotherapy is indicated for patients with symptomatic PAD to reduce the risk of cardiovascular events .
Carotid Endarterectomy and Vascular Surgery
Clopidogrel is increasingly used in patients undergoing carotid endarterectomy (CEA), especially those with symptomatic carotid disease. Its use has not been associated with increased postoperative complications, including bleeding, and is considered part of optimal medical therapy in this setting .
Special Considerations: Pharmacogenetics and Drug Interactions
The effectiveness of clopidogrel depends on its activation by the CYP2C19 enzyme. Patients with certain CYP2C19 genetic variants (intermediate or poor metabolizers) may have reduced response to clopidogrel and higher risk of adverse cardiovascular events, particularly after PCI Lee2022Johnson2012. Pharmacogenetic testing can help guide therapy in these cases .
Clopidogrel is a prodrug and can interact with other medications that affect CYP enzymes, such as some statins and proton pump inhibitors. However, there is no consistent evidence that these interactions significantly impact clinical outcomes, and necessary co-medications should not be withheld .
Use in Patients Requiring Oral Anticoagulation
In patients who require oral anticoagulation (OAC) after procedures like drug-eluting stent implantation or transcatheter aortic-valve implantation (TAVI), clopidogrel is often chosen as the P2Y12 inhibitor due to its safety profile. However, adding clopidogrel to OAC increases bleeding risk, so therapy should be individualized Goedel2019Nijenhuis2020.
Other Emerging Indications
Recent research suggests clopidogrel may have a role in inhibiting renal fibrosis in chronic kidney disease, though this is not yet a standard indication .
Conclusion
Clopidogrel is indicated for the prevention of cardiovascular events in patients with ACS, after PCI, in high-risk TIA or minor stroke, and in symptomatic PAD. It is also used in vascular surgery settings like CEA and in patients requiring OAC after stent placement. Genetic factors and drug interactions can influence its effectiveness, and therapy should be tailored to individual patient risk profiles Patti2020Lee2022Johnson2012+5 MORE.
Sources and full results
Most relevant research papers on this topic
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
This guideline updates the 2013 CPIC guideline for clopidogrel use based on CYP2C19 genotype, expanding indications and strengthening recommendations for intermediate metabolizers.
P2Y12 inhibitor, Clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.
Clopidogrel effectively inhibits renal fibrosis in chronic kidney disease by blocking macrophage-to-myofibroblast transition through TGF-/Smad3 signaling.
Clopidogrel: A Case for Indication‐Specific Pharmacogenetics
Clopidogrel genotype has a differential impact on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention, but not for other clopidogrel indications.
Impact of Continued Clopidogrel use on Outcomes of Patients undergoing Carotid Endarterectomy.
Clopidogrel use during carotid endarterectomy has increased over time and is not associated with an increased risk of postoperative complications, including bleeding.
Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.
Enhanced platelet inhibition by clopidogrel is associated with an increased risk of major bleeding and death in patients on oral anticoagulation undergoing PCI.
DOI